$ALMS

Schroer John R. sold $87K of ALMS

Schroer John R. (Chief Financial Officer) sold 3,282 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Schroer John R.
Published Aug 5, 2026, 10:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALMS
Neutral
medium confidence
Mentioned
$ALMS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale of 3,282 shares at $26.37, totaling about $86.5K, with holdings after the trade of 24,718 shares.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the disclosure lacks any fundamental catalyst or magnitude that would typically drive repricing.

03

What to watch

The article does not state motivations, tax events, or whether other insiders are buying/selling, so the signal quality is limited.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05 after-hours; sale dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for ALUMIS INC. (ALMS).

Company-level read

Ticker impact

$ALMSNeutralMedium confidence
Context

ALMS CFO John R. Schroer filed a Form 4 selling 3,282 shares at $26.37 on 2026-08-03, disclosing direct insider selling activity.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source Form 4, but the article provides only a single open-market sale and no accompanying company-specific catalyst, guidance, or legal/regulatory development.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales are often pre-planned for liquidity or diversification; the absence of a 10b5-1 plan does not necessarily imply negative information.

Key entities

  • ALUMIS INC.

    Company whose insider transaction is disclosed via SEC Form 4.

  • John R. Schroer

    Chief Financial Officer who sold shares in an open-market transaction.

Related articles

$ALMSMedAI 9/10

Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements

Alumis Inc. (ALMS) shares drew three analyst price-target raises after its Q1 2026 results and progress on envudeucitinib. Chardan lifted its target to $40 from $38 (Buy), Wells Fargo to $51 from $49 (Overweight), and Guggenheim to $34 from $32 (Buy). The company reported $569.5M cash and narrowed net loss to $93.1M; envudeucitinib Week 24 PASI 90/100 results were also cited.